Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: Effects of thrombin inhibition by argatroban and enoxaparin

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 2, 2007, Pages 407-413

  Li, Nailin ^a   He, Shu ^a   Blombäck, Margareta ^a   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coagulation; Exercise; Fibrin gel permeability; Fibrinolysis; Leukocytes; Platelets; Thrombin inhibition

Indexed keywords

ADENOSINE DIPHOSPHATE; ARGATROBAN; CD11B ANTIGEN; ELASTASE; ENOXAPARIN; PLACEBO; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; BOLUS INJECTION; CELL INTERACTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; EXERCISE; FIBRINOLYSIS; GEL PERMEATION CHROMATOGRAPHY; HEMOSTASIS; HUMAN; IN VITRO STUDY; LEUKOCYTE ACTIVATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADULT; ANTICOAGULANTS; ANTIGENS, CD11B; BLOOD COAGULATION; BLOOD PLATELETS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENOXAPARIN; EXERCISE; FIBRINOLYSIS; HUMANS; LEUKOCYTES; MALE; PANCREATIC ELASTASE; PIPECOLIC ACIDS; PLATELET ACTIVATION; THROMBIN;

EID: 33846460040     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000253906.19648.ac     Document Type: Article

References (26)

1. Willich SN, Lewis M, Löwel H, Arntz H-R, Schubert F, Schröder R. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med. 1993;329:1684-1690.
2. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD. Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 1993;88:1502-1511.
3. Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation. 1999;100:1374-1379.
4. Wang JS, Li YS, Chen JC, Chen YW. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Arterioscler Thromb Vasc Biol. 2005;25:454-460.
5. Perneby C, Wallen NH, Hu H, Li N, Hjemdahl P. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. Thromb Res. 2004;114:235-243.
6. El-Sayed MS. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Medicine. 1996;22:282-298.
7. Hilberg T, Eichler E, Glaser D, Prasa D, Sturzebecher J, Gabriel HH. Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM. Thromb Haemost. 2003;90:1065-1073.
8. Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmstrom M, He S. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinol. 2005;16:585-596.
9. He S, Zhu K, Vedin J, Svensson J, Egberg N, Blombäck M, Wallén NH. A physiological relevant assay with a computerized calculation model used to determine the haemostatic balance in plasma:Method design and preliminary application in prothrombotic patients. Revised manuscript submitted to Thromb Haemost.
10. He S, Cao H, Antovic A, Blombäck M. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinol. 2005;16:61-67.
11. Chesebro JH, Toschi V, Lettino M, Gallo R, Badimon JJ, Fallon JT, Fuster V. Evolving concepts in the pathogenesis and treatment of arterial thrombosis. Mt Sinai J Med. 1995;62:275-286.
12. Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation. 2003;108:III28-III37.
13. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-1040.
14. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP, Jr. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503-516.
15. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28:609-618.
16. Sakamoto S, Hirase T, Suzuki S, Tsukamoto T, Miki T, Yamada T, Matsuo T. Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty. Thromb Haemost. 1995;74:801-802.
17. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP, Jr. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999;33:1879-1885.
18. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Makijarvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135-142.
19. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ, Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol. 2003;41:20-25.
20. Lewis BE, Matthai WH, Jr., Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.
21. Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943-1950.
22. Hjemdahl P, Chronos NA, Wilson DJ, Bouloux P, Goodall AH. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb. 1994;14:77-84.
23. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994;89:1951-1957.
24. Allen DH, Tracy PB. Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem. 1995;270:1408-1415.
25. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2005;25:1321-1324.
26. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378-3384.